At a two-day WHO meeting in Brussels, experts
demonstrated that newly developed avian influenza vaccines could bring about a
potentially protective immune response against strains of H5N1 virus found in
This was a third such meeting in just two years and its objective was to review the progress in the development of candidate vaccines against the pandemic avian influenza
(bird flu) viruses and to reach consensus on future priority activities.
Some of the vaccines work with low doses of antigen, which effectively means that significantly more vaccine doses can be available in case of a pandemic. More than 100 influenza vaccine experts from the academia, national and regional public health institutions, the pharmaceutical industry and regulatory bodies throughout the world-attended the meeting convened by the WHO Initiative for Vaccine Research
and the WHO Global Influenza Programme
It is reported that 16 manufacturers from ten countries are developing prototype pandemic influenza vaccines against H5N1 avian influenza virus.